Mechanistically, miR-139–5p targets GALNT2 to suppress large tumor suppressor kinase 2 (LATS2) activation, thereby driving ccRCC proliferation, revealing the miR-139–5p–GALNT2–LATS2 axis as a novel therapeutic opportunity [204]. This evidence concerns the gene LATS2 and nonpapillary renal cell carcinoma.